Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2010 1
2012 1
2013 2
2014 6
2015 2
2016 2
2017 4
2018 1
2019 1
2020 5
2021 4
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J, Hald Jacobsen S, Mahlangu J, Mathias M, Nogami K, Skovgaard Rasmussen J, Stasyshyn O, Tran H, Vilchevska K, Villarreal Martinez L, Windyga J, You CW, Zozulya N, Zulfikar B, Jiménez-Yuste V; explorer7 Investigators. Matsushita T, et al. Among authors: stasyshyn o. N Engl J Med. 2023 Aug 31;389(9):783-794. doi: 10.1056/NEJMoa2216455. N Engl J Med. 2023. PMID: 37646676 Clinical Trial.
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.
Srivastava A, Rangarajan S, Kavakli K, Klamroth R, Kenet G, Khoo L, You CW, Xu W, Malan N, Frenzel L, Bagot CN, Stasyshyn O, Chang CY, Poloskey S, Qiu Z, Andersson S, Mei B, Pipe SW. Srivastava A, et al. Among authors: stasyshyn o. Lancet Haematol. 2023 May;10(5):e322-e332. doi: 10.1016/S2352-3026(23)00037-6. Epub 2023 Mar 29. Lancet Haematol. 2023. PMID: 37003278 Clinical Trial.
Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.
Sidonio RF Jr, Thompson AA, Peyvandi F, Stasyshyn O, Yeoh SL, Sosothikul D, Antmen AB, Maggiore C, Engl W, Ewenstein B, Tangada S. Sidonio RF Jr, et al. Among authors: stasyshyn o. Expert Rev Hematol. 2023 Jul-Dec;16(10):793-801. doi: 10.1080/17474086.2023.2247160. Epub 2023 Sep 7. Expert Rev Hematol. 2023. PMID: 37646148
The international factor IX treatment network survey.
Berntorp E, Shapiro AD, Waters J, Astermark J; International Factor IX Treatment Network. Berntorp E, et al. Haemophilia. 2012 May;18(3):e60-2. doi: 10.1111/j.1365-2516.2012.02767.x. Epub 2012 Mar 8. Haemophilia. 2012. PMID: 22404549 No abstract available.
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors.
Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. Pipe SW, et al. Among authors: stasyshyn o. Haemophilia. 2022 Jul;28(4):548-556. doi: 10.1111/hae.14563. Epub 2022 Apr 27. Haemophilia. 2022. PMID: 35475308 Free PMC article. Clinical Trial.
Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study.
Mahlangu J, Abdul Karim F, Stasyshyn O, Korczowski B, Salazar B, Lucas S, Suen A, Goldstein B, Chung T, Pabinger I. Mahlangu J, et al. Among authors: stasyshyn o. Res Pract Thromb Haemost. 2022 Feb 14;6(2):e12665. doi: 10.1002/rth2.12665. eCollection 2022 Feb. Res Pract Thromb Haemost. 2022. PMID: 35224416 Free PMC article.
Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).
Solano Trujillo MH, Stasyshyn O, Rusen L, Serban M, Lamas JL, Perina FG, Urasinski T, Oh M, Knowlton WB, Valenta-Singer B, Pavlova BG, Abbuehl B. Solano Trujillo MH, et al. Among authors: stasyshyn o. Haemophilia. 2014 Sep;20(5):674-81. doi: 10.1111/hae.12444. Epub 2014 Apr 10. Haemophilia. 2014. PMID: 24720694 Clinical Trial.
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Escobar M, Luck J, Averianov Y, Ducore J, Fernández MFL, Giermasz A, Hart DP, Journeycake J, Kessler C, Leissinger C, Mahlangu J, Martinez LV, Miesbach W, Mitha IH, Quon D, Reding MT, Schved JF, Stasyshyn O, Vilchevska KV, Wang M, Windyga J, Alexander WA, Al-Sabbagh A, Bonzo D, Mitchell IS, Wilkinson TA, Hermans C. Escobar M, et al. Among authors: stasyshyn o. Haemophilia. 2021 Nov;27(6):911-920. doi: 10.1111/hae.14418. Epub 2021 Oct 6. Haemophilia. 2021. PMID: 34614267 Free PMC article. Clinical Trial.
Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study).
Djambas Khayat C, Iosava G, Romashevskaya I, Stasyshyn O, Lopez MJ, Pompa MT, Rogosch T, Seifert W. Djambas Khayat C, et al. Among authors: stasyshyn o. J Blood Med. 2021 Jun 21;12:483-495. doi: 10.2147/JBM.S299130. eCollection 2021. J Blood Med. 2021. PMID: 34188580 Free PMC article.
31 results